From our latest research e-newsletter
Humans and animals with lupus produce autoantibodies that can cause inflammation, as well as damage cells and organs of one’s own body. In particular, antibodies to double-stranded DNA contribute to organ damage. Researchers have long investigated the possibility of blocking the actions of lupus-related autoantibodies to reduce the extent of such damage. Typically, such research is first tested in animals to ensure efficacy and safety before being conducted in humans. Researchers at The Feinstein Institute for Medical Research have created a new experimental molecule to test its ability to inhibit lupus-related autoantibody attachment to ds-DNA isolated from mice, as well as to components of kidneys extracted from mice, and to living brain cells of mice. The results of these studies provide hope for the development of more specific, less toxic therapies for lupus. However, more animal research is needed before this molecule can be tested in living humans with lupus.
Want to read these summaries earlier? Sign up for our newsletters here.